G2TT
来源类型Report
规范类型报告
DOIhttps://doi.org/10.7249/RR2891
来源IDRR-2891-BIOG
Assessing the Preparedness of the Australian Health Care System Infrastructure for an Alzheimer's Disease-Modifying Therapy
Sangita M. Baxi; Federico Girosi; Jodi L. Liu
发表日期2019-11-11
出版年2019
页码24
语种英语
结论
  • If a hypothetical therapy becomes available in 2023, and health system capacity follows historical growth trends, this analysis suggests that Australians could wait over ten months in the initial year to access the therapy.
  • The most pressing constraint is the availability of dementia specialists to evaluate and diagnose patients, followed by average waiting times of a few months for biomarker testing to confirm diagnosis and infusion delivery of the treatment.
  • The first year without wait times would be 2034. By eliminating wait lists that delay access to the therapy, an estimated 54,000 people would not progress from mild cognitive impairment due to AD to Alzheimer's dementia between 2023 and 2033.
摘要

Disease-modifying therapies to prevent or delay the progression of Alzheimer's disease (AD) are under clinical investigation. AD is the leading cause of dementia, and the more than 800,000 Australians with mild cognitive impairment in 2018 could potentially benefit from a therapy that reduces the risk of progression to dementia.

,

This report assesses the magnitude of the potential health system challenges in the diagnosis and treatment of early-stage Alzheimer's disease in Australia, given the hypothetical availability of a disease-modifying therapy. The authors use a simulation model to compare the expected number of patients with the capacity of the health system and assess three possible constraints: visits to dementia specialists, biomarker testing, and infusion delivery. They find that the most pressing constraint is the availability of dementia specialists to evaluate and diagnose patients, followed by average waiting times of a few months for biomarker testing to confirm diagnosis and infusion delivery of the treatment. By eliminating wait lists that delay people from accessing the therapy, they estimate that 54,000 Australians would not progress from mild cognitive impairment due to AD to Alzheimer's dementia between 2023 and 2033.

,

Although the analysis includes simplifying assumptions and is not predictive of the future, the intention is to facilitate discussions among stakeholders. Multiple stakeholders would need to coordinate reimbursement, workforce and capacity planning, and outreach efforts to ensure that people with early-stage AD would have timely access if a therapy becomes available.

目录 Assessing the Preparedness of the Australian Health Care System Infrastructure for an Alzheimer's Disease-Modifying Therapy | RAND
主题Alzheimer's Disease and Dementias ; Australia ; Health Care Services Capacity ; Mental Health Treatment
URLhttps://www.rand.org/pubs/research_reports/RR2891.html
来源智库RAND Corporation (United States)
引用统计
资源类型智库出版物
条目标识符http://119.78.100.153/handle/2XGU8XDN/523931
推荐引用方式
GB/T 7714
Sangita M. Baxi,Federico Girosi,Jodi L. Liu. Assessing the Preparedness of the Australian Health Care System Infrastructure for an Alzheimer's Disease-Modifying Therapy. 2019.
条目包含的文件
文件名称/大小 资源类型 版本类型 开放类型 使用许可
RAND_RR2891.pdf(558KB)智库出版物 限制开放CC BY-NC-SA浏览
1600098894339.jpg(6KB)智库出版物 限制开放CC BY-NC-SA缩略图
浏览
个性服务
推荐该条目
保存到收藏夹
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Sangita M. Baxi]的文章
[Federico Girosi]的文章
[Jodi L. Liu]的文章
百度学术
百度学术中相似的文章
[Sangita M. Baxi]的文章
[Federico Girosi]的文章
[Jodi L. Liu]的文章
必应学术
必应学术中相似的文章
[Sangita M. Baxi]的文章
[Federico Girosi]的文章
[Jodi L. Liu]的文章
相关权益政策
暂无数据
收藏/分享
文件名: RAND_RR2891.pdf
格式: Adobe PDF
文件名: 1600098894339.jpg
格式: JPEG

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。